Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT ID: NCT00087490
Last Updated: 2012-08-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1077 participants
INTERVENTIONAL
2004-10-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
linezolid
vancomycin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signs and symptoms consistent with infection
* Infection suspected to be due to Methicillin Resistant Staphylococcus Aureus
Exclusion Criteria
* Subjects with uncomplicated skin or superficial skin structure infection such as superficial/simple cellulitis, impetiginous lesion, furuncle, or simple abscess that only need surgical drainage for cure.
* Subjects excluded with necrotizing fasciitis, gas gangrene, osteomyelitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Montgomery, Alabama, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Palm Springs, California, United States
Pfizer Investigational Site
Rancho Mirage, California, United States
Pfizer Investigational Site
San Pedro, California, United States
Pfizer Investigational Site
Santa Fe Springs, California, United States
Pfizer Investigational Site
Sylmar, California, United States
Pfizer Investigational Site
Torrance, California, United States
Pfizer Investigational Site
Torrance, California, United States
Pfizer Investigational Site
Torrance, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Hartford, Connecticut, United States
Pfizer Investigational Site
Hartford, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
Atlantis, Florida, United States
Pfizer Investigational Site
Melbourne, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Pensacola, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Augusta, Georgia, United States
Pfizer Investigational Site
Blue Ridge, Georgia, United States
Pfizer Investigational Site
Honolulu, Hawaii, United States
Pfizer Investigational Site
Honolulu, Hawaii, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Decatur, Illinois, United States
Pfizer Investigational Site
Hines, Illinois, United States
Pfizer Investigational Site
Maywood, Illinois, United States
Pfizer Investigational Site
North Chicago, Illinois, United States
Pfizer Investigational Site
Northlake, Illinois, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
Springfield, Illinois, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
West Roxbury, Massachusetts, United States
Pfizer Investigational Site
East Lansing, Michigan, United States
Pfizer Investigational Site
Lansing, Michigan, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Mpls, Minnesota, United States
Pfizer Investigational Site
Saint Paul, Minnesota, United States
Pfizer Investigational Site
Butte, Montana, United States
Pfizer Investigational Site
Lincoln, Nebraska, United States
Pfizer Investigational Site
Lincoln, Nebraska, United States
Pfizer Investigational Site
Somers Point, New Jersey, United States
Pfizer Investigational Site
Stony Brook, New York, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Akron, Ohio, United States
Pfizer Investigational Site
Akron, Ohio, United States
Pfizer Investigational Site
Akron, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Toledo, Ohio, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
West Reading, Pennsylvania, United States
Pfizer Investigational Site
Ducktown, Tennessee, United States
Pfizer Investigational Site
Jackson, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Fort Worth, Texas, United States
Pfizer Investigational Site
Forth Worth, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
St. George, Utah, United States
Pfizer Investigational Site
St. George, Utah, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Buenos Aires, Buenos Aires, Argentina
Pfizer Investigational Site
Loma Hermosa, Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Córdoba, , Argentina
Pfizer Investigational Site
Charleroi, , Belgium
Pfizer Investigational Site
Ghent, , Belgium
Pfizer Investigational Site
Montigny-le-Tilleul, , Belgium
Pfizer Investigational Site
São José do Rio Preto, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Providencia, Santiago Metropolitan, Chile
Pfizer Investigational Site
Santiago, , Chile
Pfizer Investigational Site
Barranquilla, Atlántico, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Floridablanca, Santander Department, Colombia
Pfizer Investigational Site
Genova, , Italy
Pfizer Investigational Site
Napoli, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Udine, , Italy
Pfizer Investigational Site
Varese, , Italy
Pfizer Investigational Site
Kuala Lumpur, , Malaysia
Pfizer Investigational Site
Kuala Lumpur, , Malaysia
Pfizer Investigational Site
Guadalajara, Jalisco, Mexico
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Pragal, Almada, Portugal
Pfizer Investigational Site
Amadora, , Portugal
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Smolensk, , Russia
Pfizer Investigational Site
Singapore, Singapore, Singapore
Pfizer Investigational Site
Kuilsriver, Western Province, South Africa
Pfizer Investigational Site
Johannesburg, , South Africa
Pfizer Investigational Site
Parow, , South Africa
Pfizer Investigational Site
Pretoria, , South Africa
Pfizer Investigational Site
Pretoria, , South Africa
Pfizer Investigational Site
Córdoba, Cordoba, Spain
Pfizer Investigational Site
Girona, Gerona, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Winchester, Hampshire, United Kingdom
Pfizer Investigational Site
Edinburgh, , United Kingdom
Pfizer Investigational Site
Leeds, , United Kingdom
Pfizer Investigational Site
Ciudad Bolívar, Bolívar, Venezuela
Pfizer Investigational Site
Distrito Capital, Miranda, Venezuela
Pfizer Investigational Site
Distrito Capital, Miranda, Venezuela
Pfizer Investigational Site
Valencia, Valencia, Venezuela
Pfizer Investigational Site
Maracaibo, Zulia, Venezuela
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Puzniak LA, Morrow LE, Huang DB, Barreto JN. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther. 2013 Oct;35(10):1557-70. doi: 10.1016/j.clinthera.2013.08.001. Epub 2013 Sep 3.
Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther. 2012 Aug;34(8):1667-73.e1. doi: 10.1016/j.clinthera.2012.06.018. Epub 2012 Jul 6.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5951002
Identifier Type: -
Identifier Source: org_study_id